Meeting
2021 ASCO Annual Meeting
Multicentre retrospective assessment of toxicity and response to immunotherapy in elderly patients with metastatic melanoma.
Authors
Shivanshan Pathmanathan
Department of Oncology, Gold Coast University Hospital, Gold Coast, QLD, Australia
Shivanshan Pathmanathan , Hari S Babu , Robert Mason , Saw Htut , Zulfiquer Ali Otty , Megan Lyle , Marcin Radoslaw Dzienis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9565)
DOI
10.1200/JCO.2021.39.15_suppl.9565
Abstract #
9565
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
First Author: Erika Richtig
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Outcomes of immunotherapy in advanced melanoma in relation to age.
First Author: Krishna Prasad Joshi
Poster
2015 ASCO Annual Meeting
Effect of prednisone and rituximab prephase on early toxicity in older DLBCL patients (pts) receiving RCHOP within a NHL specific comprehensive geriatric assessment (CGA) trial.
First Author: Colette Ngozi Owens
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.
First Author: Ana-Alicia Beltran-Bless